Drug Approval | May 19, 2026
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Baxfendy works in a fundamentally different way from current therapies
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
Medanta expanded its bed capacity by 20% during the year
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Subscribe To Our Newsletter & Stay Updated
